Trastuzumab-based chemotherapy modulates systemic redox homeostasis in women with HER2-positive breast cancer

International Immunopharmacology

Volumn 27, Issue 1, 2015, Pages 8-14

  Lemos, L G T ^a   Victorino, V J ^b   Herrera, A C S A ^a   Aranome, A M F ^c   Cecchini, A L ^c   Simao A N C ^c   Panis, C ^d   Cecchini, R ^c  

^a INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c STATE UNIVERSITY OF LONDRINA   (Brazil)

^d UNIVERSIDADE ESTADUAL DO OESTE DO PARANÁ   (Brazil)

Author keywords

Breast cancer; HER2; Inflammatory status; Oxidative stress; Trastuzumab

Indexed keywords

ADVANCED OXIDATION PROTEIN PRODUCT; C REACTIVE PROTEIN; CREATINE KINASE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MALONALDEHYDE; NITRIC OXIDE; PACLITAXEL; THIOL; TRASTUZUMAB; URIC ACID; ANTINEOPLASTIC AGENT; AUTACOID; ERBB2 PROTEIN, HUMAN; THIOL DERIVATIVE;

ADULT; ANTIOXIDANT ASSAY; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL FEATURE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; GENE OVEREXPRESSION; HEART INJURY; HOMEOSTASIS; HUMAN; HUMAN TISSUE; INFLAMMATION; LIPID PEROXIDATION; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PRIORITY JOURNAL; AGED; BREAST NEOPLASMS; CANCER STAGING; CARCINOMA, DUCTAL; DRUG EFFECTS; METABOLISM; MIDDLE AGED; MOLECULARLY TARGETED THERAPY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; C-REACTIVE PROTEIN; CARCINOMA, DUCTAL; DRUG THERAPY; FEMALE; HOMEOSTASIS; HUMANS; INFLAMMATION MEDIATORS; LIPID PEROXIDATION; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; NITRIC OXIDE; OXIDATION-REDUCTION; RECEPTOR, ERBB-2; SULFHYDRYL COMPOUNDS; TRASTUZUMAB;

EID: 84928954240     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2015.04.037     Document Type: Article

References (49)

1. A. Jemal, F. Bray, M.M. Center, J. Ferlay, E. Ward, and D. Forman Global cancer statistics Cancer J. Clin. 61 2011 69 90
2. J. Lee, S. Giordano, and J. Zhang Autophagy, mitochondria and oxidative stress: cross-talk and redox signaling Biochem. J. 441 2012 523 540
3. A. Maxmen The hard facts Nature 485 2012 S50 S51
4. D.J. Slamon, G.M. Clark, S.G. Wong, W.J. Levin, A. Ullrich, and W.L. Mcguire Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 1987 177 182
5. H.M. Stern Improving treatment of HER2-positive cancers: opportunities and challenges Sci. Transl. Med. 4 2012 1 10
6. J.W. Park, R.M. Neve, J. Szollosi, and C.C. Benz Unraveling the biologic and clinical complexities of HER2 Clin. Breast Cancer 8 2008 392 401
7. I. Rubin, and Y. Yarden The basic biology of HER2 Ann. Oncol. 12 2001 S3 S8
8. C.Y. Chang, H.L. Chan, H.Y. Lin, T.D. Way, M.C. Kao, M.Z. Song, Y.J. Lin, and C.W. Lin Rhein induces apoptosis in human breast cancer cells Evid. Based Complement. Alternat. Med. 2011 2012 1 8
9. X.F. Wang, P.K. Witting, B.A. Salvatore, and J. Neuzil Vitamin E analogs trigger apoptosis in HER2/erbB2-overexpressing breast cancer cells by signaling via the mitochondrial pathway Biochem. Biophys. Res. Commun. 326 2 2005 282 389
10. D. Harari, and Y. Yarden Molecular mechanisms underlying ErbB2/HER2 action in breast cancer Oncogene 19 2000 6102 6114
11. V. Aranda, T. Haire, M.E. Nolan, J.P. Calarco, A.Z. Rosenberg, J.P. Fawcett, T. Pawson, and S.K. Muthuswamy Par6-aPKC uncouples ErbB2 induced disruption of polarized epithelial organization from proliferation control Nat. Cell Biol. 8 2006 1235 1245
12. A.H. Kim, G. Khursigara, X. Sun, T.F. Franke, and M.V. Chao Akt phosphorylates and negatively regulates apoptosis signal-regulating kinase Mol. Cell. Biol. 21 2001 893 901
13. T. Dittmar, A. Husemann, Y. Schewe, J. Nofer, B. Niggemann, K.S. Zänker, and B.H. Brandt Induction of cancer cell migration by epidermal growth factor is initiated by specific phosphorylation of tyrosine 1248 of c-erbB-2 receptor via EGFR1 FASEB J. 2002 1823 1825
14. M. Zeglinski, A. Ludke, D.S. Jasser, and P.K. Singal Trastuzumab-induced cardiac dysfunction: a "dual-hit" Exp. Clin. Cardiol. 16 3 2011 70 74
15. B. Halliwell Oxidative stress and cancer: have we moved forward? Biochem. J. 401 2007 1 11
16. D.K. Biswas, Q. Shi, S. Baily, I. Strickland, S. Ghosh, A.B. Pardee, and J.D. Iglehart NF-kB activation in human breast cancer specimens and its role in cell proliferation and apoptosis PNAS 101 27 2004 10137 10142
17. K.N. Schmidt, P. Amstad, P. Cerutti, and P.A. Baeuerle Identification of hydrogen peroxide as the relevant messenger in the activation pathway of transcription factor NF-kappaβ Adv. Exp. Med. Biol. 387 1996 63 68
18. J. Baselga, L. Norton, J. Albanell, Y.M. Kim, and J. Mendelsohn Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts Cancer Res. 58 1998 2825 2831
19. L.I. Gordon, M.A. Burke, A.T.K. Singh, S. Prachand, E.D. Lieberman, L. Sun, T.J. Naik, S.V.N. Prasad, and H. Ardehali Blockade of the erbB2 receptor induces cardiomyocyte death through mitochondrial and reactive oxygen species-dependent pathways J. Biol. Chem. 284 4 2009 2080 2087
20. C.A. Hudis Trastuzumab-mechanism of action and use in clinical practice N. Engl. J. Med. 357 2007 39 51
21. W. Tsang, and G. Moe Trastuzumab and heart failure Cardiol. Rounds 8 2007 1 6
22. C. Panis, A.C. Herrera, V.J. Victorino, A.M.F. Aranome, and R. Cecchini Screening of circulating TGF-β level and its clinicopathological significance in human breast cancer Anticancer Res. 33 2 2013 737 742
23. C. Panis, L.G.T. Lemos, V.J. Victorino, A.C.S.A. Herrera, F.C. Campos, A.N. Colado-Simão, P. Pinge-Filho, A.L. Cecchini, and R. Cecchini Immunological effects of taxol and adryamicin in breast cancer patients Cancer Immunol. Immunother. 61 2012 481 488
24. C. Panis, A.C.S.A. Herrera, V.J. Victorino, F.C. Campos, L.F. Freitas, T. De Rossi, A.N. Colado-Simão, A.L. Cecchini, and R. Cecchini Oxidative stress and hematological profiles of advanced breast cancer patients subjected to paclitaxel or doxorubicin chemotherapy Breast Cancer Res. Treat. 133 2012 89 97
25. INCA Instituto Nacional do Câncer: estimative of cancer incidence for 2012/2013 in Brazil Available in: http://www.inca.gov.br (Accessed Jul 19, 2013)
26. B. Leyland-Jones, K. Gelmon, J.P. Ayoub, A. Arnold, S. Verma, R. Dias, and P. Ghahramani Pharmacokinetics, safety and efficacy of trastuzumab administered every three weeks in combination with paclitaxel J. Clin. Oncol. 21 21 2003 3965 3971
27. A.C.S.A. Herrera, C. Panis, V.J. Victorino, F.C. Campos, A.N. Colado-Simão, A.L. Cecchini, and R. Cecchini Molecular status is determinant on inflammatory status and immunological profile from invasive breast cancer patients Cancer Immunol. Immunother. 61 2012 2193 2201
28. V.J. Victorino, C. Panis, F.C. Campos, R.C. Cayres, A.N. Colado-Simão, S.R. Oliveira, A.C.S.A. Herrera, A.L. Cecchini, and R. Cecchini Decreased oxidant profile and increased antioxidant capacity in naturally postmenopausal women Age 35 2013 1411 1421
29. C. Panis, T.L. Mazzuco, C.Z.F. Costa, V.J. Victorino, V.L.H. Tatakihara, L.M. Yamauchi, S.F. Yamada-Ogatta, R. Cecchini, L.V. Rizzo, and P. Pinge-Filho Trypanosoma cruzi: effect of the absence of 5-lipoxygenase (5-LO)-derived leukotrienes on levels of cytokines, nitric oxide and iNOS expression in cardiac tissue in the acute phase of infection in mice Exp. Parasitol. 127 2011 58 65
30. M.A. Lozovoy, A.N. Simão, C. Panis, M.A. Rotter, E.M. Reiche, H.K. Morimoto, E. Lavado, R. Cecchini, and I. Dichi Oxidative stress is associated with liver damage, inflammatory status, and corticosteroid therapy in patients with systemic lupus erythematosus Lupus 20 12 2011 1250 1259
31. L. Pizzatti, C. Panis, G. Lemos, M. Rocha, R. Cecchini, G.H.M.F. Souza, and E. Abdelhay Label-free MSE proteomic analysis of chronic myeloid leukemia bone marrow plasma: disclosing new insights from therapy resistance Proteomics 12 2012 2618 2631
32. C. Panis, V.J. Victorino, A.C.S.A. Herrera, L.F. Freitas, T. De Rossi, F.C. Campos, A.N. Colado-Simão, D.S. Barbosa, P. Pinge-Filho, R. Cecchini, and A.L. Cecchini Differential oxidative status and immune characterization of the early and advanced stages of human breast cancer Breast Cancer Res. Treat. 133 2012 881 888
33. M. Gago-Dominguez, E. Castelao, M.C. Pike, A. Sevanian, and R. Haile Role of lipid peroxidation in the epidemiology and preventions of breast cancer Cancer Epidemiol. Biomarkers Prev. 14 12 2005 2829 2839
34. F. Manello, V. Medda, and G.A. Tonti Protein profile analysis of the breast microenvironment to differentiate healthy women from breast cancer patients Expert Rev. Proteomics 6 1 2009 43 60
35. M. López-Lázaro Dual role of hydrogen peroxide in cancer: possible relevance to cancer chemoprevention and therapy Cancer Lett. 252 1 2007 1 8
36. F. Manello, and J.D. Raffetto Matrix metalloproteinase activity and glycosaminoglycans in chronic venous disease: the linkage among cell biology, pathology and translational research Am. J. Transl. Res. 3 2 2011 149 158
37. G. Minotti, P. Menna, E. Salvatorelli, G. Cairo, and L. Gianni Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity Pharmacol. Rev. 56 2004 185 229
38. J. Alexandre, C. Nicco, C. Chéreau, A. Laurent, B. Weill, F. Goldwasser, and F. Batteux Improvement of the therapeutic index of anticancer drugs by the superoxide dismutase mimic mangafodipir J. Natl. Cancer Inst. 98 4 2006 236 244
39. E. Azambuja, P.L. Bedard, T. Suter, and M. Piccart-Gebhart Cardiac toxicity with anti-HER2 therapies - what have we learned so far? Target. Oncol. 4 2009 77 78
40. B. Halliwell, and M. Whiteman Measuring reactive species and oxidative damage in vivo and in cell culture: how should you do it and a what do the results mean? Br. J. Pharmacol. 142 2004 231 255
41. R. Radi, J.S. Beckman, K.M. Bush, and B.A. Freeman Peroxynitrite oxidation to sulfhydryls J. Biol. Chem. 266 7 2001 4244 4250
42. H. Rubbo, R. Radi, M. Trujillo, R. Telleri, B. Kalyanaraman, S. Barnes, M. Kirk, and B.A. Freeman Nitric oxide regulation of superoxide and peroxynitrite-dependent lipid peroxidation J. Biol. Chem. 269 42 1994 26066 26075
43. B. Halliwell Tell me about free radicals, doctor: a review J. R. Soc. Med. 82 1989 747 752
44. A. Ghiselli, M. Serafini, F. Natella, and C. Scaccini Total antioxidant capacity as a tool assess redox status: critical view and experimental data Free Radic. Biol. Med. 29 11 2000 1106 1114
45. J.D. Hayes, and D. Pulford The glutathione S-transferase supergene family: regulation of GST and the contribution to the isoenzymes to cancer chemoprotection and drug resistance Crit. Rev. Biochem. Mol. Biol. 30 6 1995 445 600
46. S.A. Crone, Y.Y. Zhao, L. Fan, Y. Gu, S. Minamisawa, Y. Liu, K.L. Peterson, J. Chen, R. Kahn, G. Condorelli, J. Ross Jr., K.R. Chien, and K.F. Lee ErbB2 is essential in the prevention of dilated cardiomyopathy Nat. Med. 8 5 2002 459 465
47. L.P. Grazzette, W. Boecker, T. Matsui, M. Semigran, T.L. Force, R.J. Hajjar, and A. Rosenzweig Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: Implications for herceptin-induced cardiomyopathy J. Am. Coll. Cardiol. 44 11 2004 2231 2238
48. C. Yazici, K. Kose, M. Calis, S. Kuzuguden, and M. Kirnap Protein oxidation status in patients with ankylosing spondylitis Rheumatology 43 2004 1235 1239
49. V.J. Victorino, F.C. Campos, A.C. Herrera, A.N. Colado Simão, A.L. Cecchini, C. Panis, and R. Cecchini Overexpression of HER2/neu protein attenuates the oxidative systemic profile in women diagnosed with breast cancer Tumor Biol. 35 4 2014 3025 3034